The anticoagulant ‘Xarelto (ingredient name: Rivaroxaban)’ developed by Bayer was used as a vitamin K antagonist in patients with Non-Valvular Atrial Fibrillation (NVAF) accompanied by Chronic Kidney Disease (CKD). , VKA) compared to the clinical benefit was confirmed.
Bayer presented XARENO data, a prospective registry observational study of Xarelto, at the annual meeting of the American Heart Association (ACC 2022) held on the 2nd-4th.
Chronic kidney disease is an independent risk factor for cardiovascular disease, and it is estimated that 15-20% of patients with atrial fibrillation also have chronic kidney disease.
Because patients with atrial fibrillation with impaired renal function have a higher risk of stroke and bleeding, prevention of renal decline in the selection of oral anticoagulants for patients with atrial fibrillation is an important therapeutic goal that should be considered in addition to stroke prevention.
In the XARENO study, among patients with NVAF with advanced chronic kidney disease, patients with VKA or patients not taking oral anticoagulants (at the discretion of the attending physician) and patients with Xarelto were compared.
Key outcome indicators included chronic kidney disease progression and total clinical benefit (stroke and other thromboembolism, major hemorrhage, and death from any cause).
After one year of follow-up, Xarelto showed a greater total clinical benefit and a lower risk of renal failure compared to VKA in NVAF patients with advanced chronic kidney disease.
Following ROCKET-AF, a randomized controlled trial, Xarelto added evidence of prescribing to patients with renal impairment, including stage 4 chronic kidney disease patients. In addition, it has prepared a wider clinical basis compared to other NOACs (New Oral Anticoagulants) in the preservation of renal function.
The 2019 American Heart Association, Heart Association, and Arrhythmia Society (AHA, ACC, HRS) guidelines are different from other NOACs with a trough of the therapeutic range in patients with atrial fibrillation with renal impairment. It is recommended for use in patients with less than
Professor Reinhold Kreutz, Department of Clinical Pharmacy, Charité Medical University, Berlin, said, “Chronic kidney disease is a common condition, but it tends to be underestimated despite its serious impact on the patient’s quality of life, including death depending on the stage.” “The XARENO study will provide important evidence for medical staff treating patients with atrial fibrillation with chronic kidney disease, and will help reduce the patient’s risk of developing renal failure.”
